MGC Pharmaceuticals concludes its full capital restructuring and refinancing

oduction and development of innovative medicines for unmet medical needs, has announced that following shareholder approval at a General Meeting held on 25 October 2023, the consolidation of the Company’s total issued capital on a 1:1,000 basis has been completed, along with the settlement of the US$7.9m share placement as announced on 1 November 2023.

Upon completion of the Consolidation and Placement, the Company’s capital structure will consist of the below:

Class of Securities	Number of Securities
Fully Paid Ordinary Shares	35,430,491
Unlisted options exercisable at US$0.32 on or before 7 November 2028	15,500,000
Unlisted options (various ex. price from GBP1.20 to A$13.00, April 2024-July 2026)	858,824
Performance Rights	18,400
Convertible Notes (Mercer Opportunities Fund)	7,306,432

Click to view all articles for the EPIC: MXC
Or click to view the full company profile:

MGC Pharmaceuticals formally changes its name to Argent BioPharma Ltd

2nd April 2024

Argent BioPharma Ltd (ASX:RGT), an innovative drug discovery company within the biopharmaceutical sector, has formally changed its name from MGC Pharmaceuticals Limited (ASX:MXC) to Argent BioPharma Limited as approved by shareholders at a General Meeting held

MGC Pharmaceuticals secures US$7.9 million in new fund raising

1st November 2023

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that following shareholder approval for a new share placement secured

MGC Pharmaceuticals delivers a year of great productivity and significant business growth

31st August 2023

MGC Pharmaceuticals Ltd (LON:MXC) has advised that is has released its 30 June 2023, Preliminary Financial Report, an unaudited Full Year Financial Report required under the Australian Securities Exchange’s Listing Rules. MGC Pharmaceuticals Limited (LON:MXC) is a

MGC Pharmaceuticals positive clinical trial results for CimetrA

14th August 2023

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced positive pre-clinical trial results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral

MGC Pharmaceuticals CEO on the progress of CannEpil & CimetrA (LON:MXC)

10th August 2023

MGC Pharmaceuticals’ Roby Zomer discusses what the company does, the first import of Psilocybin, highlights from the last quarter and what investors can expect in the coming months in this exclusive interview with DirectorsTalk.

MGC Pharmaceuticals on the front line of Psilocybin R&D (VIDEO)

1st August 2023

MGC Pharmaceuticals plc (LON:MXC) CEO Roby Zomer joins DirectorsTalk Interviews to discuss the granting of its first import permit for 200g of Psilocybin Raw Mushroom material. In this interview Roby reminds us of what the company does,

MGC Pharmaceuticals granted its first import permit of Psilocybin

31st July 2023

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced it has been granted its first import permit for 200g of Psilocybin Raw Mushroom material to

MGC Pharmaceuticals reports on a very productive June quarter

28th July 2023

MGC Pharmaceuticals Ltd (LON:MXC), a European based pharmaceutical company specialising in the production and development of plant derived medicines, has provided its Quarterly Activity Report for the three months ending 30th June 2023. Key Highlights: · CannEpil®, MGC

MDMA and magic mushrooms can be legally prescribed now in Australia

25th July 2023

Early adopter in this space is MGC Pharmaceuticals (ASX:MXC), has positioned itself as a key player in pioneering psychedelic research and development. What a time to be alive. As the clock struck midnight to herald the start

MGC Pharmaceuticals pleased with Australia’s reclassification of psychedelic compounds

3rd July 2023

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has welcomed the new regulation in Australia making it the first country to allow psychiatrists to prescribe psychedelics to

MGC Pharmaceuticals appoints Mr. Layton Mills as a Non-Executive Director

1st June 2023

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced the appointment of Mr. Layton Mills as a Non-Executive Director of the Company effective immediately. Mr. Mills

MGC Pharmaceuticals CannEpil received by first patients in the UK

31st May 2023

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced that CannEpil®, MGC Pharma’s IMP has now been successfully imported and received by its first patients in

MGC Pharmaceuticals appoints Dr Stephen Parker as interim Non-Executive Chair

30th May 2023

MGC Pharmaceuticals Ltd (ASX:MXC), a European based pharmaceutical company specialising in production and development of plant inspired medicines, has announced the following changes to the Board and its lead UK advisers, as a further development in its pharmaceutical

Be sure to check our sister interview main ratings news website